|
Morbidity, Mortality and Improvement Conference |
03/26/2024 - 4:00pm to 5:00pm CDT |
|
Rhabdoid Tumor Predisposition Syndrome with SMARCB1 Mutation and Novel Approaches in Treatment |
04/09/2024 - 4:00pm to 5:00pm CDT |
|
Treatment-Related Osteonecrosis in Hematology/Oncology Patients: An Overview of Risk Factors, Treatment and Management Strategies |
04/16/2024 - 4:00pm to 5:00pm CDT |
|
When Healers Cannot Heal: Ethical Considerations When Oncology Treatment is Declined |
04/23/2024 - 4:00pm to 5:00pm CDT |
|
Characteristics and Outcomes of Newly Diagnosed Aml Patients Who Deviated From the Standard Cog-Based Regimens and Received Alternative Therapy |
04/30/2024 - 4:00pm to 5:00pm CDT |
|
Insights on Managing Cancer Risks in Children with Hereditary Cancer Predisposition Syndromes (An Update) |
05/07/2024 - 4:00pm to 5:00pm CDT |
|
Deciphering Hyperinflammation: Differential Diagnosis and Initial Management Strategies for Hemophagocytic Lymphohistiocytosis (HLH) |
05/14/2024 - 4:00pm to 5:00pm CDT |
|
Morbidity, Mortality and Improvement Conference: Patient/Parent-Directed Refusal of Standard Pediatric Oncologic Care |
05/21/2024 - 4:00pm to 5:00pm CDT |
|
Thrombopoietin Receptor Agonists and Acute Myeloid Leukemia |
05/28/2024 - 4:00pm to 5:00pm CDT |
|
Retinoblastoma: Current Practice of Care and Failure Directions for Refractory Disease |
06/04/2024 - 4:00pm to 5:00pm CDT |